Micropore, InnoCore Enter Injectable Drugs Collaboration

UK-based particle engineering specialist Micropore Technologies has entered a collaboration and license agreement with InnoCore Technologies BV, to deploy its patented technology, for the manufacture of InnoCore’s SynBiosys long acting injectable drugs.
 
Based in Groningen, The Netherlands, InnoCore has developed sophisticated biodegradable polymer formulation technologies for long acting injectable, sustained release microparticle-based drug delivery products. Its SynBiosys biodegradable polymer platform enables systemic and site-specific parenteral drug delivery of small molecule, peptide and protein drugs with extended release duration from days up to several months.
 
Micropore’s patented, GMP standard, high-throughput membrane encapsulation technology will allow InnoCore to continuously produce precisely controlled high-quality encapsulated products at volumes previously only possible using traditional homogenization techniques, but with more predictability and higher yields and reduced processing costs.
 
Through enabling InnoCore to process more evenly sized micro-particles, Micropore’s equipment will result in products offering more precisely controllable dose levels with narrower release time parameters because unwanted rupture variability in the product can be virtually eliminated.
 
In addition, because Micropore’s patented technology is based on a crossflow technique utilizing tubular membranes, with no moving parts, the minimal shear forces involved in producing the microcapsules will help to protect the sensitive biological drugs that InnoCore’s microparticle products incorporate from processing damage.
 
"We are delighted with this symbiotic collaboration," said Dai Hayward, chief executive officer, Micropore. "We have been looking for the opportunity to demonstrate the inherent advantages of our technology in a cGMP application. Our capability of delivering near-monodispersity in formulations and encapsulated particles will enable InnoCore to optimize the efficacy of their long acting injectable controlled-release formulations and facilitate scale-up for high volume throughput production."
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.